GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » Debt-to-Revenue

Abattis Bioceuticals (Abattis Bioceuticals) Debt-to-Revenue : 1.73 (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Abattis Bioceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $1.09 Mil. Abattis Bioceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was $0.09 Mil. Abattis Bioceuticals's annualized Revenue for the quarter that ended in Sep. 2019 was $0.68 Mil. Abattis Bioceuticals's annualized Debt-to-Revenue for the quarter that ended in Sep. 2019 was 1.73.


Abattis Bioceuticals Debt-to-Revenue Historical Data

The historical data trend for Abattis Bioceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals Debt-to-Revenue Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - N/A N/A - 4.39

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.91 1.73

Competitive Comparison of Abattis Bioceuticals's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's Debt-to-Revenue falls into.



Abattis Bioceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Abattis Bioceuticals's Debt-to-Revenue for the fiscal year that ended in Sep. 2019 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.092 + 0.094) / 0.27
=4.39

Abattis Bioceuticals's annualized Debt-to-Revenue for the quarter that ended in Sep. 2019 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.092 + 0.094) / 0.684
=1.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2019) Revenue data.


Abattis Bioceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines